Enveric Biosciences, Inc. (ENVB)
1.45
-0.02
(-1.36%)
USD |
NASDAQ |
Oct 07, 11:59
Enveric Biosciences Net Income (Quarterly) : -3.028M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -3.028M |
| March 31, 2026 | -1.634M |
| December 31, 2025 | -2.194M |
| September 30, 2025 | -1.874M |
| June 30, 2025 | -2.519M |
| March 31, 2025 | -2.185M |
| December 31, 2024 | -3.155M |
| September 30, 2024 | -2.084M |
| June 30, 2024 | -1.879M |
| March 31, 2024 | -2.457M |
| December 31, 2023 | -3.436M |
| September 30, 2023 | -2.822M |
| June 30, 2023 | -6.356M |
| March 31, 2023 | -4.678M |
| December 31, 2022 | -8.678M |
| September 30, 2022 | -2.479M |
| June 30, 2022 | -2.790M |
| March 31, 2022 | -4.524M |
| December 31, 2021 | -42.11M |
| September 30, 2021 | -2.712M |
| June 30, 2021 | -0.9083M |
| March 31, 2021 | -3.251M |
| September 30, 2020 | -0.5653M |
| June 30, 2020 | -0.8184M |
| March 31, 2020 | -1.098M |
| Date | Value |
|---|---|
| December 31, 2019 | -2.529M |
| September 30, 2019 | 0.0413M |
| June 30, 2019 | -1.257M |
| March 31, 2019 | -1.86M |
| December 31, 2018 | -19.76M |
| September 30, 2018 | 5.700M |
| June 30, 2018 | -1.260M |
| March 31, 2018 | -1.572M |
| December 31, 2017 | -1.024M |
| September 30, 2017 | -4.061M |
| June 30, 2017 | -3.264M |
| March 31, 2017 | -0.7255M |
| December 31, 2016 | 1.304M |
| September 30, 2016 | -1.718M |
| June 30, 2016 | -1.209M |
| March 31, 2016 | -1.160M |
| December 31, 2015 | -1.752M |
| September 30, 2015 | -0.2494M |
| June 30, 2015 | 0.111M |
| March 31, 2015 | -0.0026M |
| December 31, 2014 | -0.0107M |
| September 30, 2014 | -0.0032M |
| June 30, 2014 | -0.0119M |
| March 31, 2014 | -0.0079M |
| December 31, 2013 | 0.013M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| LENZ Therapeutics, Inc. | -31.92M |
| Impact BioMedical, Inc. | -0.70M |
| ANI Pharmaceuticals, Inc. | 23.00M |
| Corcept Therapeutics, Inc. | 42.14M |
| Veru, Inc. | -6.988M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 3.028M |
| EPS Diluted (Quarterly) | -0.7594 |
| Enterprise Value | -2.510M |
| Earnings Yield | -1.14K% |
| Normalized Earnings Yield | -1135.17 |